GRI
GRI Bio, Inc.
$2.17
+8.50%
$3.8M
No data for this timeframe.
Vol
Market Cap$3.8M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (83%)
SEC Reports1
Recent Activity
May 18, 2026
routine
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
<p align="center"><i>Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on We
May 14, 2026
SEC
GRI Bio reported Q1 2026 financial results with a net loss of $2.0M (improved from $3.0M in Q1 2025) and cash of $11.0M,
8-K — Impact 5/10
Price Targets
$21.00
+854.5% upside
Strong Buy
Current $2.20
Low $10.00
Median $21.00
High $32.00
2 analysts
$10.00
$32.00
Analyst Ratings
1Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Mar 11, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.20 ▲ +67.8% | $-1.24 — $-1.15 | 97% YoY | 2 |
| Next Q | $-1.08 ▲ +71.8% | $-1.21 — $-0.95 | 97% YoY | 2 |
| Current FY | $-4.77 ▲ +69.0% | $-5.13 — $-4.41 | 96% YoY | 2 |
| Next FY | $-2.54 ▲ +68.4% | $-4.81 — $-0.26 | 47% YoY | 2 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (83% buy). Based on 6 analysts: 1 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$21.00 mean target
+854.5% upside
Strong Buy (1.00)
$10.00 Low
$32.00 High
| Metric | Value |
|---|---|
| Current Price | $2.20 |
| Target Low | $10.00 |
| Target Mean | $21.00 |
| Target Median | $21.00 |
| Target High | $32.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.20 | $-1.24 | $-1.15 | 96.7% | +67.8% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-1.08 | $-1.21 | $-0.95 | 97.0% | +71.8% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-4.77 | $-5.13 | $-4.41 | 96.1% | +69.0% | — | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-2.54 | $-4.81 | $-0.26 | 46.9% | +68.4% | — | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.195 | |
| 7d ago | $-1.150 | -0.045 |
| 30d ago | $-3.715 | +2.520 |
| 60d ago | $-3.715 | +2.520 |
| 90d ago | $-19.320 | +18.125 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| May 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Apr 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Mar 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Feb 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jan 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 18, 2026
routine
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
<p align="center"><i>Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026</i></p>
May 14, 2026
earnings
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
<p align="center"><i>Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active a
May 13, 2026
earnings_calendar
GRI Q1 2026 Earnings Scheduled — 2026-05-13
Apr 8, 2026
other
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
<p align="center"><i>Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand str